NCT07065630View on ClinicalTrials.gov

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 17, 2026

Primary Completion Date

August 13, 2029

Study Completion Date

August 13, 2029

Conditions
Head and Neck CancerHPV
Interventions
DRUG

Volrustomig

500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.

DRUG

Carboplatin

100mg/m2 IV day 1 and day 8.

DRUG

Paclitaxel

AUC 5 IV day 1

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER